Treatment and Management of Women With Bleeding Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-01-31

Study Completion Date

2006-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine whether oral contraceptives, desmopressin acetate, and/or tranexamic acid are effective in the treatment of women with menorrhagia who are diagnosed with a bleeding disorder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders

NCT03834727

Hemophilia A Bleeding Disorder

COMPLETED

Tranexamic Acid and Depot-Medroxyprogesterone Acetate for Perimenopausal Irregular Uterine Bleeding

NCT04710017

Uterine Bleeding

COMPLETED NA

Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery

NCT00885924

Hemorrhage Postoperative Blood Loss

TERMINATED PHASE4

Tranexamic Acid in Pregnancies With Vaginal Bleeding

NCT03632824

Vaginal Bleeding During Pregnancy

COMPLETED NA

World Maternal Antifibrinolytic Trial_2

NCT03475342

Intrapartum - Moderate and Severe Anaemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Menorrhagia is a common clinical problem. Morbid events include dysmenorrhea, hospitalizations, red blood cell transfusions, and quality of life impairment in terms of daily activities, chronic pain, and time lost from work and or school. Up to 60% of women with uncontrolled menorrhagia undergo hysterectomy. Up to 20% of women with menorrhagia may have undiagnosed von Willebrand disease (vWd), or other bleeding disorders. Prevalence of vWd in the general population is estimated at just over 1%. Intuitively, the prevalence of vWd in women with menorrhagia is probably higher since platelet plug formation is necessary for menstrual hemostasis. Current management of menorrhagia in patients in the United States often begins with hormonal therapy. Estrogen and estrogen derivatives in oral contraceptives have been shown to increase von Willebrand factor (vWf) levels. Women with menorrhagia who have vWd or who are hemophilia A carriers have also been successfully treated with desmopressin acetate (DDAVP, Stimate® Nasal Spray). Tranexamic acid (Cyklokapron) is utilized extensively for menorrhagia in Australia and the United Kingdom. Standard hormonal therapy has not been compared with desmopressin or antifibrinolytics for menorrhagia. This study will compare treatment options for women with menorrhagia who have a detectable bleeding disorder. Investigators will document the effect on quality of life, menstrual flow, and coagulation parameters of treatment with oral contraceptive pills, desmopressin, or tranexamic acid.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menorrhagia Blood Coagulation Disorders Blood Platelet Disorders Von Willebrand Disease Hematologic Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tranexamic Acid

Intervention Type DRUG

Desmopressin Acetate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Referred to study by gynecologist or internist/family practitioner with diagnosis of menorrhagia or referred by self through community advertising or networking
* Prospective pictorial chart scores of menses \>100
* Negative pelvic exam and Pap smear within the past year. \*Ultrasound if manual exam indicates abnormal uterine size; \*Endometrial biopsy if \>35 and non-cyclic bleeding; \*Rule out acute pelvic diseases - gonorrhea, chlamydia
* Age 18-50
* Willing to go off oral contraceptives and selected drugs (including some nutritional supplements and drugs that affect coagulation such as aspirin and ibuprofen) for initial laboratory testing and throughout the cross-over drug portion of the study
* Periods at least every 39 days

Exclusion Criteria

* Patient is not proficient in English
* Patient is pregnant
* Patient on hormone replacement, Depo-Provera, or Norplant in last three months
* Patient has intrauterine device (IUD) present
* Patient is taking warfarin sodium (Coumadin) or other anti-coagulation therapy
* History of documented vascular disease (coronary artery disease, cerebrovascular disease or stroke, transient ischemic attack, peripheral vascular disease)
* Uncontrolled hypertension
* Insulin dependent diabetes mellitus
* Chronic renal or liver disease
* History of seizure disorder
* History of cancer (other than non-invasive skin cancer)
* History of venous or arterial thromboembolism
* Patient with a previously diagnosed bleeding disorder has taken or is taking desmopressin acetate or antifibrinolytic drugs for treatment of heavy menstrual bleeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No